Dave Asprey Says Biden's FDA Banned Cheap Peptides to Protect Ozempic — Here's What Actually Happened
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated June 2026
Dave Asprey Says Biden's FDA Banned Cheap Peptides to Protect Ozempic — Here's What Actually Happened
A prominent biohacker made a direct accusation: the Biden administration's FDA deliberately banned affordable peptides to protect the market share of billion-dollar GLP-1 drugs like Ozempic. Now, with the Make America Healthy Again (MAHA) movement gaining traction inside the federal government, some are asking whether those bans will be reversed.
It's a bold claim. But the timeline of events — and the paper trail of FDA actions — makes it worth looking at closely.
Important: I'm not a doctor. Everything shared here is based on published reporting, regulatory documents, and cited research. Talk to your physician before making any changes to your health regimen.
The Bottom Line
- Dave Asprey publicly claimed that the Biden-era FDA banned low-cost peptides — including compounds like BPC-157 and CJC-1295 — while simultaneously allowing Ozempic and Wegovy to dominate the market.
- The FDA did take a series of actions between 2023 and 2025 that restricted compounded semaglutide and placed several research peptides on restricted lists — cutting off access for many patients who relied on cheaper alternatives.
- Asprey and others in the biohacker/wellness space argue this was regulatory capture — the pharmaceutical industry influencing government agencies to protect profits.
- The MAHA movement, closely associated with Health Secretary Robert F. Kennedy Jr., has signaled interest in reforming FDA peptide policy.
- Actionable takeaway: If you currently use or are considering compounded peptides, watch FDA docket activity closely in Q3 2025 — that is when regulatory guidance updates are expected. Nothing has changed yet as of this writing (May 2026).
What Dave Asprey Actually Said
Dave Asprey — founder of Bulletproof Coffee, author, and one of the most recognized names in the biohacking community — made the claim in a widely circulated interview and follow-up post covered by SeattleRed.com.
His core argument, in plain English: the FDA under the Biden administration moved to shut down access to affordable peptide compounds while doing nothing to reduce the $1,000-per-month price tag on FDA-approved GLP-1 drugs like Ozempic and Wegovy.
Asprey specifically called out the FDA's decisions around compounding pharmacies. He argued that peptides available through licensed compounding pharmacies — at a fraction of the cost of branded drugs — were systematically restricted, forcing patients into more expensive options or off the market entirely.
He framed it as a pattern of regulatory capture: pharmaceutical companies using their influence over federal agencies to eliminate cheaper competition.
It is important to note: Asprey has a history of making provocative claims, and not all of them hold up to scrutiny. But on this particular issue, the regulatory record is worth examining on its own merits.
The Regulatory Timeline: What the FDA Actually Did
To understand whether Asprey's accusation has any basis, here is the documented sequence of FDA actions:
2021–2022: Compounded Semaglutide Becomes Popular
As Ozempic demand surged and supply shortages emerged, compounding pharmacies began producing semaglutide — the active ingredient in Ozempic — at dramatically lower prices. Some patients were paying $100–$200 per month for compounded versions versus $800–$1,000+ for the branded drug.
The FDA allowed this under shortage exemptions. Compounding pharmacies are legally permitted to produce copies of drugs listed on the FDA's drug shortage list.
Late 2023: FDA Puts Semaglutide on the Shortage List — Then Takes It Off
In October 2023, the FDA officially listed semaglutide as being in shortage. This formally opened the door for compounding pharmacies to legally produce it at scale.
Then, in February 2025, the FDA declared the semaglutide shortage resolved — meaning the legal basis for compounded semaglutide largely disappeared.
The result: compounding pharmacies received notices that they needed to stop producing semaglutide or face enforcement action. The FDA set a wind-down deadline of April 2025 for most providers.
For patients who had been paying $150/month for compounded semaglutide, this was a direct price shock — pushing them either to branded Ozempic/Wegovy at full price or off the medication entirely.
2023–2024: Several Research Peptides Added to Restricted Lists
Separately, the FDA moved to add a number of peptides — including BPC-157, selank, and others — to the "Category 2" list under the 503A and 503B compounding frameworks. This effectively prohibited licensed compounding pharmacies from including these compounds in preparations for patients.
BPC-157, in particular, had developed a significant following for its reported role in gut health and recovery. It is a research compound and is not FDA-approved for human use. However, many patients had been accessing it through compounding pharmacies with physician oversight.
Note: BPC-157 is classified as a research compound and is not FDA-approved for human use. Information about it here is educational only and not a recommendation to use it.
The FDA's stated rationale was that these compounds lacked sufficient evidence of safety and effectiveness for human use — a scientifically defensible position. But critics noted the timing: restrictions on affordable alternatives came during the same window as the GLP-1 drug market exploded into one of the most profitable pharmaceutical segments in history.
April 2025: Compounding Ban Enforcement Begins
The FDA began active enforcement against compounding pharmacies still producing semaglutide. This directly affected hundreds of thousands of patients.
At the same time, tirzepatide — the active ingredient in Mounjaro and Zepbound — was also removed from shortage status, setting up a similar crackdown on compounded tirzepatide.
Is Asprey Right? The Regulatory Capture Argument
Regulatory capture is a real and documented phenomenon. It refers to a situation where a regulatory agency, over time, comes to serve the interests of the industry it is supposed to regulate rather than the public.
There is a credible case to be made that some FDA decisions around peptides and compounding disproportionately benefited large pharmaceutical manufacturers. Here is what supports that reading:
The timing is notable. The escalation of restrictions on compounded semaglutide and research peptides coincided almost exactly with Novo Nordisk and Eli Lilly's GLP-1 drugs becoming the highest-grossing pharmaceutical products in the world.
The price differential is significant. Compounded semaglutide was available for roughly 80–90% less than branded versions. For a drug prescribed to millions of Americans, that gap represents enormous lost revenue for manufacturers.
Industry lobbying was active. Novo Nordisk's lobbying expenditures were publicly reported at over $10 million in 2023 alone, with significant activity around FDA compounding policy — this is verifiable through federal lobbying disclosure records.
Here is what complicates the regulatory capture argument:
The FDA's safety rationale is not invented. The agency's concerns about compounding quality control are legitimate. Compounding pharmacies operate under less regulatory oversight than pharmaceutical manufacturers, and there have been documented cases of contamination and dosing errors in compounded products.
The shortage resolution determination has a process. The FDA's declaration that the semaglutide shortage was resolved was based on reported supply data from manufacturers — though critics have argued that "shortage resolved" does not mean "affordable and accessible."
Research peptide restrictions predate the GLP-1 boom. Some of the compounding framework restrictions on research peptides had roots in FDA policy going back further than the current GLP-1 controversy, though enforcement escalated noticeably.
The honest answer is: the evidence is consistent with both regulatory overreach influenced by industry interests and legitimate public health enforcement. Those two things can be true simultaneously. The full picture is messier than either Asprey's framing or the FDA's defense would suggest.
Where MAHA Comes In
The Make America Healthy Again movement — closely associated with Robert F. Kennedy Jr. in his role as Secretary of Health and Human Services — has made FDA reform a central plank of its platform.
Kennedy and the MAHA coalition have been explicitly critical of what they call agency capture by pharmaceutical companies. Their stated policy agenda includes:
- Reviewing and potentially reversing restrictions on compounded medications
- Increasing access to alternative and less expensive therapeutic options
- Scrutinizing the revolving door between FDA staff and the pharmaceutical industry
Kennedy's HHS has signaled that a review of compounding pharmacy policy is underway, though as of this writing no formal regulatory changes have been finalized.
Asprey has been vocal in supporting the MAHA direction on this issue, arguing that the movement represents the first serious political effort to break what he sees as a corrupt relationship between the FDA and the pharmaceutical industry.
What MAHA has NOT done yet, as of May 2026:
- Reversed the compounded semaglutide ban
- Restored BPC-157 or other peptides to compounding-eligible status
- Issued new guidance on research peptide access
- Published a formal review timeline
In other words: the rhetoric has shifted, but the regulatory reality on the ground has not changed yet.
What This Means for People Who Use Peptides
If you were using compounded semaglutide or tirzepatide and lost access, here is where things stand practically:
Your legal options are limited right now. Compounding pharmacies cannot legally produce semaglutide or tirzepatide for most patients under current FDA enforcement. There are still some limited exceptions for specific patient populations with documented medical need and documented inability to access the branded product.
Some telehealth providers are offering workarounds. Oral semaglutide formulations and certain peptide analogs are being marketed as alternatives. Approach these with significant caution and verify the legal and safety status of anything you consider.
The policy environment is shifting, but slowly. If MAHA's stated goals translate into actual regulatory action, compounded GLP-1s and some research peptides could regain legal access pathways. Watch for FDA docket updates and Federal Register notices — those are where real policy changes first appear.
Talk to your doctor. If you relied on compounded peptides for a specific health goal, a physician who is knowledgeable about peptides and compounding can help you understand what options still exist and what is coming.
The Broader Context: Peptides as Regulatory Battleground
The fight over peptide access is not really about any single compound. It is about who controls access to emerging therapeutic tools, and at what price.
On one side: a regulatory framework built primarily to evaluate single-molecule pharmaceutical drugs, which does not map well onto the broader world of peptides, many of which are smaller, naturally occurring, and have significant published research despite lacking the billion-dollar clinical trial programs required for FDA approval.
On the other side: a pharmaceutical industry that has invested enormously in FDA-approved GLP-1 drugs and has significant financial interest in limiting competition.
In the middle: millions of patients who found affordable access through compounding pharmacies and are now caught in the crossfire of a regulatory and political dispute that was never really about their health in the first place.
Asprey's claim is provocative, and he is not a neutral observer. But the question he is raising — whether the FDA's peptide restrictions serve public health or pharmaceutical profits — is a legitimate one that deserves a straight answer. The current policy record does not provide one clearly.
FAQ
Did the FDA ban all peptides? No. The FDA took specific actions to restrict compounded semaglutide and tirzepatide after declaring drug shortages resolved, and added certain research peptides to restricted lists under compounding frameworks. Many peptides remain available as research compounds, though they cannot be legally dispensed by compounding pharmacies for human use in most cases.
Is compounded semaglutide still available? As of May 2026, the FDA has restricted most compounding pharmacy production of semaglutide. Limited exceptions may exist for specific patient populations. The enforcement began in April 2025 after the FDA declared the shortage resolved.
What is MAHA and how does it relate to FDA peptide policy? MAHA (Make America Healthy Again) is a health-focused political movement associated with Health Secretary Robert F. Kennedy Jr. It has signaled interest in reforming FDA compounding and peptide policy, but has not yet implemented formal regulatory changes as of this writing.
What did Dave Asprey specifically claim? Asprey claimed the Biden-era FDA deliberately banned affordable peptides and compounded drugs while protecting the market position of high-cost pharmaceutical GLP-1 drugs like Ozempic and Wegovy. He characterized this as regulatory capture.
What is regulatory capture? Regulatory capture refers to a situation where a government agency designed to regulate an industry instead begins to act in that industry's interests. It is a documented phenomenon studied in economics and political science, and has been alleged — with varying degrees of evidence — across multiple federal agencies.
What to Watch Next
The regulatory picture on peptides is genuinely in flux. Here are the specific signals worth tracking:
- FDA Federal Register notices on compounding pharmacy policy updates
- HHS/MAHA formal policy announcements regarding peptide access
- Congressional activity on the compounding pharmacy access issue — several bills were introduced in 2025 that would modify FDA authority here
- Court rulings — multiple compounding pharmacy associations have filed legal challenges to the semaglutide and tirzepatide compounding bans
This story is not over. The outcome will materially affect how millions of Americans access and pay for metabolic health tools over the next decade.
We will update this post as the regulatory situation develops.
Post published: May 5, 2026
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.
Sources
- FDA Drug Shortage Database — Semaglutide — FDA.gov
- FDA Compounding Policy — 503A and 503B Frameworks — FDA.gov
- Senate HELP Committee Compounding Pharmacy Hearing Documentation — U.S. Senate, 2024
- Federal Lobbying Disclosure Records — Novo Nordisk — U.S. Senate Lobbying Disclosure Database
- SeattleRed.com — Dave Asprey interview coverage — SeattleRed, 2025
- FDA Enforcement Actions on Compounded Semaglutide — April 2025 — FDA.gov
- HHS MAHA Initiative Overview — U.S. Department of Health and Human Services
- BPC-157 Compounding Restriction Notice — FDA.gov
- Glucagon-like peptide-1 receptor agonists — PubMed research overview — PubMed, 2024
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.